USPTO serial 75487713
POLY MASC
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- CHARLON, BARNEY
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with POLY MASC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
DONNA J BUNTON
DONNA J BUNTON NIXON & VANDERHYE PC1100 N GLEBE RD 8TH FLARLINGTON, VA 22201-4714UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | POLYMER DERIVATIVES AND POLYETHYLENE GLYCOL DERIVATIVES FOR USE IN THE MANUFACTURE OF THERAPEUTIC AND DIAGNOSTIC AGENTS AND IMAGING AGENTS FOR DIAGNOSTIC PURPOSES; POLYMER DERIVATIVES AND POLYETHYLENE GLYCOL DERIVATIVES FOR USE IN THE MANUFACTURE OF COSMETIC AND PHARMACEUTICAL PREPARATIONS AND SUBSTANCES; POLYMER BEADS FOR USE IN MANUFACTURING; POLYALKYLENE GLYCOLS FOR USE IN THE MANUFACTURE OF THERAPEUTIC AND DIAGNOSTIC AGENTS AND IMAGING AGENTS FOR DIAGNOSTIC PURPOSES; LIPOSOMES, PROTEINS AND PEPTIDES FOR USE IN THE MANUFACTURE OF PHARMACEUTICALS; DIAGNOSTIC AGENTS AND REAGENTS FOR MEDICAL RESEARCH USE; POLYMER MODIFIED COMPOUNDS FOR USE IN THE MANUFACTURE OF THERAPEUTIC AND DIAGNOSTIC AGENTS; IMAGING AGENTS FOR DIAGNOSTIC PURPOSES | ACTIVE | — |
| 005 | PHARMACEUTICAL AND VETERINARY PREPARATIONS AND SUBSTANCES; NAMELY, PROTEINS, PEPTIDES, AMINO ACIDS AND THEIR DERIVATIVES, NAMELY, ANTIBODIES AND FRAGMENTS THEREOF; CYTOKINES AND DERIVATIVES OR FRAGMENTS THEREOF, NAMELY, THE INTERLEUKINS IL, ESPECIALLY THE IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10 AND IL-11 SUBTYPES THEREOF; COLONY STIMULATING FACTORS, NAMELY, GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR, GRANULOCYTE-COLONYSTIMULATING FACTOR, ALPHA AND BETA FORMS, AND MACROPHAGE-COLONY STIMULATING FACTOR, ALSO KNOWN AS CSF-1; HAEMOPOIETINS, NAMELY, ERYTHROPOIETIN, HAEMOPOIETIN-ALPHA AND KIT-LIGAND, ALSO KNOWN AS STEM CELL FACTOR OR STEEL FACTOR; INTERFERONS IFNS, NAMELY, IFNALPHA, IFNBETA,IFNGAMMA; GROWTH FACTORS AND BIFUNCTIONAL GROWTH MODULATORS, NAMELY, EPIDERMAL GROWTH FACTOR, PLATELET-DERIVED GROWTH FACTOR, TRANSFORMING GROWTH FACTOR, ALPHA AND BETA FORMS, AMPHIREGULIN, SOMATOMEDIN-C, BONE GROWTH FACTOR, FIBROBLAST GROWTH FACTORS, INSULIN-LIKE GROWTH FACTORS, HERAPIN BINDING GROWTH FACTORS AND TUMOR GROWTH FACTORS; DIFFERENTIATION FACTORS AND THE LIKE, NAMELY, MACROPHAGE DIFFERENTIATING FACTOR, DIFFERENTIATION INDUCING FACTOR DIF AND LEUKAEMIAINHIBITORY FACTOR; ACTIVATING FACTORS, NAMELY, PLATELET ACTIVATING FACTOR; COAGULATION FACTORS SUCH AS FIBRINOLYTIC/ANTICOAGULANT AGENTS INCLUDING HERAPIN AND PROTEASES AND THEIR PRO-FACTORS, NAMELY, CLOTTING FACTORS VII, VIII, IX, X, Xl, XII, ANTITHROMBIN Ill, PROTEIN C, PROTEIN 5, STREPTOKINASE, UROKINASE, PROUROKINASE, TISSUE PLASMINOGEN ACTIVATOR, FIBRINOGEN AND HIRUDIN; PEPTIDEHORMONES, NAMELY, INSULIN AND CALCITONIN; ENZYMES NAMELY, SUPEROXIDE DISMUTASE, GLUCOCEREBROSIDASE, ASPARAGINASE AND ADENOSINE DEAMINASE; TRANSCRIPTION FACTORS AND TRANSCRIPTIONAL MODULATORS; CARBOHYDRATES, GLYCOSOAMINOGLYCANS, GLYCOPROTEINS AND POLYSACCHARIDES; LIPIDS, NAMELY, PHOSPHATI DYL-ETHANOLAMINE, PHOSPHATIDYLSERINE AND DERIVATIVES THEREOF; SPHINGOSINE; STEROIDS, NAMELY, CHOLESTEROL AND DERIVATIVES THEREOF; NUCLEOTIDES, NUCLEOSIDES, HETEROCYCLIC BASES, DNA, RNA, SYNTHETIC AND NON-SYNTHETIC OLIGONUCLEOTIDES INCLUDING THOSE WITH NUCLEASE RESISTANT BACKBONES; VITAMINS; ANTIBIOTICS; BACTERISTATIC AND BACTERICIDAL AGENTS; ANTIFUNGAL, ANTHELMINTHIC AND OTHER AGENTS EFFECTIVE AGAINST INFECTIVE AGENTS INCLUDING UNICELLULAR PATHOGENS; SMALL EFFECTOR MOLECULES, NAMELY, NORADRENALIN, ALPHA ADRENERGIC RECEPTOR LIGANDS, DOPAMINE RECEPTOR LIGANDS, HISTAMINE RECEPTOR LIGANDS, GABNBENZODIAZEPINE RECEPTOR LIGANDS, SEROTONIC RECEPTOR LIGANDS, LEUKOTRIENES AND TRIIODOTHYRONINE; CYTOTOXIC AGENTS SUCH AS DOXORUBICIN, METHOTREXATE AND DERIVATIVES THEREOF; VACCINES, NAMELY, HEPATITIS-B VACCINE, MALARIA VACCINE, MELANOMA VACCINE AND HIV-1 VACCINE | ACTIVE | — |
| 010 | CATHETERS; STENTS AND PARTS AND FITTINGS FOR THESE GOODS | ACTIVE | — |
| 035 | TECHNOLOGY LICENSING SERVICES RELATING TO PHARMACEUTICALS, VETERINARY PRODUCTS, SANITARY PRODUCTS, GENE THERAPY, CANCER TREATMENT AND POLYMER TECHNOLOGY | ACTIVE | — |
| 042 | RESEARCH AND CONSULTANCY SERVICES RELATING TO PHARMACEUTICALS, VETERINARY PRODUCTS, SANITARY PRODUCTS, GENE THERAPY, CANCER TREATMENT AND POLYMER TECHNOLOGY | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PolyMASC Pharmaceuticals Plc
- Other trademarks owned by PolyMASC Pharmaceuticals Plc
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named POLY MASC
- Prosecution event ABN6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 19, 2003 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 16, 2002 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 23, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 3, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Feb 26, 2001 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 1, 2001 | CNEA | EXAMINER'S AMENDMENT MAILED | — |
| Jun 20, 2000 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 20, 1999 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 1, 1999 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 1, 1999 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 28, 1999 | DOCK | ASSIGNED TO EXAMINER | — |